Thermo Fisher Scientific (TMO) Stock Forecast & Price Target

$601.71

+2.46 (+0.41%)

(As of 10/18/2024 ET)

Thermo Fisher Scientific - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 22 Analyst Ratings

Sell
0

Hold
4

Buy
18

Based on 22 Wall Street analysts who have issued ratings for Thermo Fisher Scientific in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 22 analysts, 4 have given a hold rating, 17 have given a buy rating, and 1 has given a strong buy rating for TMO.

Consensus Price Target

$656.16
9.05% Upside

According to the 22 analysts' twelve-month price targets for Thermo Fisher Scientific, the average price target is $656.16. The highest price target for TMO is $767.00, while the lowest price target for TMO is $575.00. The average price target represents a forecasted upside of 9.05% from the current price of $601.71.

TMO Analyst Ratings Over Time

Type	Current Forecast 10/21/23 to 10/20/24	1 Month Ago 9/21/23 to 9/20/24	3 Months Ago 7/23/23 to 7/22/24	1 Year Ago 10/21/22 to 10/21/23
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	17 Buy rating(s)	15 Buy rating(s)	12 Buy rating(s)	13 Buy rating(s)
Hold	4 Hold rating(s)	4 Hold rating(s)	5 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$656.16	$647.78	$605.63	$621.13
Forecasted Upside	9.05% Upside	5.55% Upside	10.84% Upside	33.76% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

Has Trump Finally Gone Too Far? (Ad)

Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.

TMO Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

TMO Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Thermo Fisher Scientific Stock vs. The Competition

Type	Thermo Fisher Scientific	Medical Companies	S&P 500
Consensus Rating Score	2.86	2.79	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Hold
Predicted Upside	9.05% Upside	13,587.63% Upside	6.19% Upside
News Sentiment Rating	Positive News See Recent TMO News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
10/15/2024	Barclays 3 of 5 stars		Boost Target	Equal Weight ➝ Equal Weight	$600.00 ➝ $620.00	+3.04%
10/14/2024	Redburn Atlantic 0 of 5 stars	J. Clark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$680.00	+13.74%
10/1/2024	Evercore ISI 2 of 5 stars		Boost Target	Outperform ➝ Outperform	$605.00 ➝ $630.00	+2.55%
10/1/2024	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Johnson Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$680.00	+9.93%
9/20/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$615.00 ➝ $680.00	+10.76%
9/20/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$650.00 ➝ $670.00	+9.13%
Kickstart your own Weekend Side Hustle right from your couch (Ad) Today I want to show you how to start your very own Weekend Side Hustle right from the comfort of your sofa! It doesn't matter if you have a multi-million dollar retirement account… Or if you’re just starting out with a few thousand. Click here & let me show you how I am targeting extra income as early as THIS weekend!
9/20/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$655.00 ➝ $680.00	+10.95%
9/20/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$767.00 ➝ $767.00	+25.14%
9/16/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Leonard Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
9/16/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$600.00 ➝ $675.00	+10.44%
8/27/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	B. Couillard Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$670.00	+9.76%
7/25/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$648.00 ➝ $658.00	+10.32%
7/25/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$650.00 ➝ $660.00	+9.56%
7/25/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$620.00 ➝ $632.00	+9.95%
6/3/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Hold ➝ Buy	$600.00 ➝ $650.00	+14.44%
4/30/2024	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$660.00 ➝ $670.00	+17.13%
4/25/2024	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$600.00 ➝ $610.00	+6.54%
4/10/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$550.00 ➝ $640.00	+10.94%
3/18/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Neutral	$620.00	+6.70%
1/8/2024	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Market Perform
12/13/2023	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$575.00	+15.58%
10/26/2023	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Overweight ➝ Sector Weight
7/13/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Outperform	$620.00	+17.89%
2/2/2023	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$620.00 ➝ $630.00	+7.26%
2/2/2023	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$690.00 ➝ $711.00	+21.05%
10/27/2022	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 12:55 AM ET.

Should I Buy Thermo Fisher Scientific Stock? TMO Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, October 13, 2024. Please send any questions or comments about these Thermo Fisher Scientific pros and cons to contact@marketbeat.com.

Thermo Fisher Scientific
Bull Case

Here are some ways that investors could benefit from investing in Thermo Fisher Scientific Inc.:

Thermo Fisher Scientific Inc. has a strong track record of consistent earnings growth, with an expected EPS of 21.72 for the current fiscal year. This indicates financial stability and potential for future returns.
The company has a high percentage of institutional ownership at 89.23%, which signifies confidence from large investors and stability in the stock.
Recent insider selling activities totaling $14,094,292 may indicate that insiders believe the stock is overvalued, potentially prompting a correction in the stock price.
Thermo Fisher Scientific Inc. offers a quarterly dividend of $0.39 per share, with a dividend payout ratio of 10.01%. This provides investors with a steady income stream.
Analysts have given Thermo Fisher Scientific Inc. positive ratings, with an average rating of "Moderate Buy" and a consensus price target of $647.78, suggesting potential for stock price appreciation.

Thermo Fisher Scientific
Bear Case

Investors should be bearish about investing in Thermo Fisher Scientific Inc. for these reasons:

Insiders have sold a significant number of shares worth $14,094,292 over the last three months, which could be interpreted as a lack of confidence in the company's future performance.
The current stock price of Thermo Fisher Scientific Inc. may be inflated due to the high institutional ownership and positive analyst ratings, potentially leading to a price correction.
Thermo Fisher Scientific Inc.'s dividend yield of 0.26% may not be attractive to income-seeking investors compared to other dividend-paying stocks.
While the company has a strong earnings outlook, any unexpected changes in the market or industry conditions could impact its ability to meet earnings expectations.
Investing in Thermo Fisher Scientific Inc. carries market risk, as the stock price can be influenced by various external factors beyond the company's control.

TMO Forecast - Frequently Asked Questions

: According to the research reports of 22 Wall Street equities research analysts, the average twelve-month stock price forecast for Thermo Fisher Scientific is $656.16, with a high forecast of $767.00 and a low forecast of $575.00.
: 22 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Thermo Fisher Scientific in the last twelve months. There are currently 4 hold ratings, 17 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" TMO shares.
: According to analysts, Thermo Fisher Scientific's stock has a predicted upside of 9.05% based on their 12-month stock forecasts.
: Over the previous 90 days, Thermo Fisher Scientific's stock had 1 upgrade by analysts.
: Thermo Fisher Scientific has been rated by research analysts at Bank of America, Barclays, Evercore ISI, JPMorgan Chase & Co., Morgan Stanley, Raymond James, Redburn Atlantic, Robert W. Baird, Royal Bank of Canada, Stephens, Stifel Nicolaus, TD Cowen, UBS Group, and Wells Fargo & Company in the past 90 days.
: Analysts like Thermo Fisher Scientific more than other "medical" companies. The consensus rating score for Thermo Fisher Scientific is 2.86 while the average consensus rating score for "medical" companies is 2.79. Learn more on how TMO compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Kickstart your own Weekend Side Hustle right from your couch (Ad)

Today I want to show you how to start your very own Weekend Side Hustle right from the comfort of your sofa! It doesn't matter if you have a multi-million dollar retirement account… Or if you’re just starting out with a few thousand.

Click here & let me show you how I am targeting extra income as early as THIS weekend!

This page (NYSE:TMO) was last updated on 10/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

Get Started with MarketBeat

	Read Your Daily Newsletter
	Check Out My MarketBeat
	Watch Our Tutorial Videos
	Add a Stock to Your Watchlist
	Set Up an Instant Alert
	View a Company's Profile Page
	View Our Financial Calendars
	View Today's Analyst Ratings

Thermo Fisher Scientific (TMO) Stock Forecast & Price Target